Winway Health Desk
Fierce Pharma Asia—AstraZeneca-Junshi PD-1 deal; Takeda’s $1.2B diabetes selloff, Ovid epilepsy...
In a strangely structured deal, AstraZeneca licensed Junshi Biosciences' PD-1 inhibitor for just one indication in China countrywide. Takeda continued divesting noncore products with a...
Payers team up to vaccinate older Americans in underserved communities
A group of health insurers are joining forces to help get older Americans in underserved communities vaccinated with the Covid-19 vaccine.
Members of America’s Health...
Roche is gearing up to knock down an Irish plant—and it’s...
Unable to sell its plant in Clarecastle, Ireland, Roche will take a wrecking ball to the facility in June.
It won’t be a simple process....
Meet Circulo, the insurtech firm on a mission to disrupt Medicaid...
The insurtech market, which is characterized by fierce competition, recently saw a new entrant: Circulo.
Co-founded by Sean Lane — CEO of another health tech...
A year into Sanofi’s revamp, CEO Paul Hudson collects €11.34M in...
A few months after joining Sanofi in 2019, CEO Paul Hudson laid out new R&D priorities and cut bait on some operations that weren't...
Amgen’s $1.9B Five Prime deal adds to cancer drug pipeline and...
Amgen, which is looking to bolster its cancer drug pipeline and build its presence in Asia, is acquiring Five Prime Therapeutics in a $1.9...
Flexion adds ex-WNBA star Swoopes to promotion team for osteoarthritis med...
Former WNBA star Sheryl Swoopes recently joined another elite squad of athletes. The Hall of Famer and three-time Olympic gold medalist is joining Flexion Therapeutics'...
Survey: HR administrators, employees disagree on mental health coverage
Since the start of the pandemic, many companies looked for ways to bolster mental health coverage, but there’s still a disconnect between HR...
AbbVie and Sanofi, Regeneron lead pharma’s lower TV spending in February
Pharma TV advertisers’ pace of spending dropped in February, hampered by fewer days during the shorter month but also by a significant drop in spending from AbbVie’s...
Biogen cements gene therapy ambitions with $200M factory in Research Triangle
As Biogen awaits an FDA decision on its controversial Alzheimer's disease hopeful aducanumab, the company is setting the stage for an entry into the...
